Overview

A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.

Status:
Completed

Trial end date:
2010-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety of JNJ-26854165 (a new drug in development for cancer) in patients with advanced or refractory solid tumors on the maximum dose tolerated by these patients.

Phase:

Phase 1

Details

Lead Sponsor:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.